SK pharmteco Commits More Than $200 Million Over Five Years to Expand U.S. Peptide and Small-Molecule Manufacturing
Contract manufacturer SK pharmteco announced on Wednesday, September 30, 2026 a five-year investment of more than $200 million in its U.S. development and manufacturing operations, centered on its Rancho Cordova, California site. The plan adds GMP kilo-scale peptide manufacturing with advanced liquid chromatography, expected to be operating in late 2026, along with new small-molecule API suites and about 100 long-term U.S. jobs. CEO Joerg Ahlgrimm said the expansion responds to 'unprecedented demand from our broad customer base.'